ArticleCellular and molecular life sciences : CMLS2022
L007-0069 kills Staphylococcus aureus in high resistant phenotypes.
Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 againstVirulence · 2026Article
- [In vitro and in vivo antibacterial effects of the mitochondrial antioxidant Visomitin againstZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Repurposed bunamidine disrupts envelope energetics and induces ROS-mediated non-lytic killing.AMB Express · 2026Article
- Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes.Frontiers in cellular and infection microbiology · 2026Article
- Mechanisms of action of the hexane extract ofADMET & DMPK · 2026Article
- Antibacterial and Antibiofilm Activity of Closantel Against Staphylococcus epidermidis.MicrobiologyOpen · 2025Article
- Antimicrobial Action of Essential Oil ofAntibiotics (Basel, Switzerland) · 2025Article
- Novel antibiotics againstMedComm · 2025Article
- Drug repurposing of Nifuratel against methicillin-resistantFrontiers in cellular and infection microbiology · 2025Article
- Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.AMB Express · 2024Article
- Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus.Applied microbiology and biotechnology · 2024Article
- An amphipathic peptide combats multidrug-resistant Staphylococcus aureus and biofilms.Communications biology · 2024Article
- Article
- Identification of a small molecule 0390 as a potent antimicrobial agent to combat antibiotic-resistantFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Staphylococcus aureus, a common gram-positive pathogenic bacterium, is a main cause of hospital infection. The prevalence rate of methicillin-resistant S. aureus (MRSA) has made its treatment difficult in recent decades. Moreover, S. aureus in the highly tolerant format of biofilm or persister often renders infections refractory. Thus, developing new active compounds against resistant S. aureus is urgently needed. In this study, by a high-throughput screening assay, we identified a small molecule, L007-0069, that exhibited strong and effective bactericidal activity against S. aureus and its high resistance patterns, such as biofilms and persisters, with a low probability of inducing resistance. By molecular dynamics and fluorescent probe analysis, mechanistic studies revealed that the bactericidal activity of L007-0069 was mainly mediated by membrane disruption and metabolic disorder induction. Furthermore, L007-0069 showed effective anti-MRSA effects in vivo in both a wound infection model and a peritonitis-sepsis model, with no detectable toxicity observed at the therapeutic dosage. In conclusion, L007-0069 has the potential to become an alternative for the treatment of highly resistant S. aureus-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.